156 related articles for article (PubMed ID: 7653992)
1. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Powis G; Gasdaska PY; Gallegos A; Sherrill K; Goodman D
Anticancer Res; 1995; 15(4):1141-5. PubMed ID: 7653992
[TBL] [Abstract][Full Text] [Related]
2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
3. Increased NAD(P)H:(quinone-acceptor)oxidoreductase activity is associated with density-dependent growth inhibition of normal but not transformed cells.
Schlager JJ; Hoerl BJ; Riebow J; Scott DP; Gasdaska P; Scott RE; Powis G
Cancer Res; 1993 Mar; 53(6):1338-42. PubMed ID: 8443814
[TBL] [Abstract][Full Text] [Related]
4. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.
Wang X; Doherty GP; Leith MK; Curphey TJ; Begleiter A
Br J Cancer; 1999 Jun; 80(8):1223-30. PubMed ID: 10376975
[TBL] [Abstract][Full Text] [Related]
6. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
Wu K; Eng E; Knox R; Chen S
Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Sharp SY; Kelland LR; Valenti MR; Brunton LA; Hobbs S; Workman P
Mol Pharmacol; 2000 Nov; 58(5):1146-55. PubMed ID: 11040064
[TBL] [Abstract][Full Text] [Related]
9. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
Begleiter A; Leith MK; Curphey TJ
Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837
[TBL] [Abstract][Full Text] [Related]
10. Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.
Yao KS; Hageboutros A; Ford P; O'Dwyer PJ
Mol Pharmacol; 1997 Mar; 51(3):422-30. PubMed ID: 9058597
[TBL] [Abstract][Full Text] [Related]
11. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
12. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
13. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
14. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells.
Siegel D; Gibson NW; Preusch PC; Ross D
Cancer Res; 1990 Nov; 50(22):7293-300. PubMed ID: 2121335
[TBL] [Abstract][Full Text] [Related]
16. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
17. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
Gasdaska PY; Fisher H; Powis G
Cancer Res; 1995 Jun; 55(12):2542-7. PubMed ID: 7780966
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
Workman P
Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
[TBL] [Abstract][Full Text] [Related]
19. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells.
Baumann RP; Hodnick WF; Seow HA; Belcourt MF; Rockwell S; Sherman DH; Sartorelli AC
Cancer Res; 2001 Nov; 61(21):7770-6. PubMed ID: 11691791
[TBL] [Abstract][Full Text] [Related]
20. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
